source
- Pfizer, Arvinas sell recently approved breast cancer drug to Rigel for $35 millionPfizer and its partner Arvinas have agreed to transfer the commercial rights of a breast cancer therapy to Rigel Pharmaceuticals. The drug had just received regulatory approval, marking a mileston…
- Bayer signals cautious yet aggressive push into pharma acquisitions after five-year pauseBayer's CEO Bill Anderson told investors on the first-quarter earnings call that the company is ready to re-enter the pharmaceutical merger-and-acquisition market after a five-year hiatus. He emph…